摘要
单克隆抗体作为一种具有靶向性的药物在肿瘤治疗方面具有良好的效果,因此抗体药物的研发一直是国内外学者关注的焦点。目前上市的抗体药物绝大多数为IgG亚型,因其高度的特异性,Fab端能够识别并结合抗原,而Fc端通常能介导机体免疫系统发挥抗体依赖的细胞介导的细胞毒性作用(ADCC)、抗体依赖的细胞吞噬作用(ADCP)以及补体依赖的细胞毒性作用(CDC)。这些细胞毒性作用也是抗肿瘤抗体药物发挥体内药效杀伤肿瘤细胞和清除病毒感染细胞的机制之一,因此对于这一类抗体药物Fc端的药效评价在其整个生命周期内都是尤为重要的。本文就ADCC和CDC的作用机制以及各自的检测方法进行了综述,对单抗药物Fc端功能的认识以及药物质量控制奠定了基础。
Monoclonal antibodies,as a targeted drug,have shown great efficacy in tumor treatment.Therefore,the development of antibody drugs has always been a focus of attention for scholars both domestically and internationally.At present,the vast majority of antibody drugs on the market are IgG subtypes.Due to its high specificity,the Fab domain can recognize and bind antigens,while the Fc domain can usually mediate the immune system to play antibody-dependent cell-mediated cytotoxicity(ADCC),antibody-dependent cytophagocytosis(ADCP)and complement dependent cytotoxicity(CDC).These cytotoxic effects are also one of the mechanisms by which anti-tumor antibody drugs exert in vivo efficacy to kill tumor cells and clear virus-infected cells,so the evaluation of the efficacy of the Fc domain of this class of antibody drugs is particularly important throughout its life cycle.In this paper,the mechanism of action of ADCC and CDC and their respective detection methods were reviewed,and some references were provided for the understanding of Fc domain function and drug quality control of monoclonal antibodies.
作者
张坤成
孔霄玥
方雅
覃一枫
陈悦
秦国宏
ZHANG Kuncheng;KONG Xiaoyue;FANG Ya;QIN Yifeng;CHEN Yue;QIN Guohong(Department of Biology,Fanghua Pharmaceutical Research Institute,Nanjing Chia-Tai Tianqing Pharmaceutical Co.,Ltd.,Nanjing 210046,China)
出处
《山东化工》
2025年第3期119-124,共6页
Shandong Chemical Industry
